Findings

What do systematic reviews say?

3,241 questions · 3,336 findings · 1,340 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1,581 · 47.4%GRADE not reported 352 · 10.6%Very low 512 · 15.3%Low 509 · 15.3%Moderate 316 · 9.5%High 66 · 2%

Antiseptic mouthrinse vs placebo

Quality of life · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
No quality of life data were reported.
0 studies
No studies found

Bethanechol vs placebo

Quality of life · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
No data on either quality of life or other oral related symptoms were reported.
0 studies
No studies found

Chinese medicine vs no treatment/placebo

Quality of life · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
End of intervention to 3 months postRT
Insufficient evidence to determine any effect on quality of life (Lin 2014; Analysis 6.5)
1 study
GRADE not reported

Amifostine (intravenous) vs Amifostine (subcutaneous)

Quality of life · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
No data on either quality of life or other oral related symptoms were reported.
0 studies
No studies found

Beta‐carotene vs placebo

Quality of life · general population

The review found no eligible studies for this question.

1 finding from 1 review

Antioxidant vitamin and mineral supplements for preventing age‐related macular degeneration 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Vitamin C vs placebo

Quality of life · general population

The review found no eligible studies for this question.

1 finding from 1 review

Antioxidant vitamin and mineral supplements for preventing age‐related macular degeneration 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Multivitamin vs placebo

Quality of life · general population

The review found no eligible studies for this question.

1 finding from 1 review

Antioxidant vitamin and mineral supplements for preventing age‐related macular degeneration 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Vitamin E vs placebo

Quality of life · general population

The review found no eligible studies for this question.

1 finding from 1 review

Antioxidant vitamin and mineral supplements for preventing age‐related macular degeneration 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

DDAVP vs placebo or usual care

Quality of life · participants with platelet dysfunction undergoing surgery

The review found no eligible studies for this question.

1 finding from 1 review

Desmopressin use for minimising perioperative blood transfusion 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

DDAVP vs tranexamic acid (control)

Quality of life · participants undergoing surgery

The review found no eligible studies for this question.

1 finding from 1 review

Desmopressin use for minimising perioperative blood transfusion 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

DDAVP vs aprotinin

Quality of life · participants undergoing surgery

The review found no eligible studies for this question.

1 finding from 1 review

Desmopressin use for minimising perioperative blood transfusion 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

DDAVP vs placebo or usual care

Quality of life · participants undergoing surgery

The review found no eligible studies for this question.

1 finding from 1 review

Desmopressin use for minimising perioperative blood transfusion 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Bisphosphonates vs placebo/observation

Quality of life · women with advanced breast cancer without bone metastases

1 finding from 1 review

Bisphosphonates and other bone agents for breast cancer 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 124 participants
Moderate

Bisphosphonates vs placebo/observation

Quality of life · women with metastatic breast cancer with bone metastases

1 finding from 1 review

Bisphosphonates and other bone agents for breast cancer 2017 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 1888 participants
Moderate

Summary of findings table (subcomparison 1): chemotherapy or targeted therapy plus best supportive care (BSC) vs BSC

Quality of life · palliative participants with esophageal and GE‐junction carcinoma

1 finding from 1 review

Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer 2017 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 1129 participants
Very low

Summary of findings table (subcomparison 2): second‐line chemotherapy or targeted therapy agent(s) plus control intervention vs control intervention

Quality of life · palliative participants with esophageal and GE‐junction carcinoma previously treated with chemotherapy

1 finding from 1 review

Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer 2017 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 1638 participants
Very low

Summary of findings table (subcomparison 3): chemotherapy agent(s) plus control intervention vs control intervention

Quality of life · palliative participants with esophageal and GE‐junction carcinoma

1 finding from 1 review

Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer 2017 · Cochrane Headline outcomes only
no estimate extracted
450 participants
Very low

Summary of findings table (subcomparison 4): targeted therapy agent plus control intervention vs control intervention

Quality of life · palliative participants with esophageal and GE‐junction carcinoma

1 finding from 1 review

Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer 2017 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 2054 participants
Very low

Summary of findings table (subcomparison 5): chemotherapy or targeted therapy agent(s) plus control intervention vs control intervention

Quality of life · palliative participants with AC of the esophagus

1 finding from 1 review

Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer 2017 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 1772 participants
Very low

Summary of findings table (subcomparison 5): chemotherapy or targeted therapy agent(s) plus control intervention vs control intervention

Quality of life · palliative participants with SCC of the esophagus

1 finding from 1 review

Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 156 participants
Very low